


## Paprottrain

Cat. No.:	HY-101298
CAS No.:	57046-73-8
Molecular Formula:	C <sub>16</sub> H <sub>11</sub> N <sub>3</sub>
Molecular Weight:	245.28
Target:	Kinesin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 100 mg/mL (407.70 mM) * "≥" means soluble, but saturation unknown.					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	4.0770 mL	20.3849 mL	40.7697 mL
			5 mM	0.8154 mL	4.0770 mL	8.1539 mL
			10 mM	0.4077 mL	2.0385 mL	4.0770 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (10.19 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	Paprottrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC <sub>50</sub> of 1.35 μM and a K <sub>i</sub> of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC <sub>50</sub> of 5.5 μM.
IC <sub>50</sub> & Target	MKLP-2 1.35 μM (IC <sub>50</sub> )
In Vitro	Paprottrain has been screened on a panel of CNS kinases. While inactive (IC <sub>50</sub> > 10 μM) on CDK5 and GSK3, it has shown a moderate activity on DYRK1A (IC <sub>50</sub> = 5.5 μM) <sup>[1]</sup> . Time-lapse microscopy shows that disrupting MKlp2 expression with paprottrain results in polar body extrusion failure. This could be rescued after rescuing oocytes from paprottrain in fresh medium. Cell cycle analysis shows that most oocytes are arrested at metaphase I or telophase I. However, oocyte spindle structure and chromosome alignment are not disrupted after the inhibition of MKlp2 by paprottrain <sup>[2]</sup> . Paprottrain-treated porcine oocytes suffer failure of nuclear maturation. The number of oocytes arrested at early MI stage increase in a dose-dependent manner after KIF20A activity inhibition, while the percentage of oocytes that reach ATI and MII stages decrease

after treatment<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Kinase Assay <sup>[1]</sup>

Kinase activities for each enzyme are assayed in the presence of 15  $\mu$ M ATP in a final volume of 30  $\mu$ L. After 30 min incubation at 30°C, the reaction is stopped by harvesting, using a FilterMate harvester, onto P81 phosphocellulose papers which are washed in 1% phosphoric acid. 20  $\mu$ L of scintillation fluid are added and the incorporated radioactivity measured in a Packard counter. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during the 30 min incubation. Controls are performed with appropriate dilutions of DMSO. Kinase activities are expressed in % of maximal activity, i.e. in the absence of inhibitors (Paprottrain). IC50 values are obtained from the dose-response curves<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### Cell Assay <sup>[3]</sup>

COCs or denuded oocytes (DOs) are cultured in the presence/absence of Paprottrain in vitro. The control groups are performed with pure DMSO at the same concentration. COCs are denuded of their cumulus cells by gentle pipetting with 0.1% (w/v) hyaluronidase. Oocytes with clearly extruded polar bodies are judged to be matured oocytes. After cultured for 44 h, the polar body extrusion rate of matured oocytes is observed using a microscope. Furthermore, chromosomal alignments and the cell cycle of oocytes treated with inhibitor are examined using laser scan confocal microscopy<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Urol Oncol. 2023 Feb 20;S1078-1439(23)00010-8.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Labrière C, et al. Further investigation of Paprottrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. Eur J Med Chem. 2016 Nov 29;124:920-934.
- [2]. Liu J, et al. MKlp2 inhibitor paprottrain affects polar body extrusion during mouse oocyte maturation. Reprod Biol Endocrinol. 2013 Dec 21;11:117.
- [3]. Zhang Y, et al. KIF20A regulates porcine oocyte maturation and early embryo development.
- [4]. Tcherniuk S, et al. Relocation of Aurora B and survivin from centromeres to the central spindle impaired by a kinesin-specific MKLP-2 inhibitor. Angew Chem Int Ed Engl. 2010 Oct 25;49(44):8228-31.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA